相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?
Zhen Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He et al.
MEDICINAL RESEARCH REVIEWS (2022)
Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2
Huanhuan Zhao et al.
CELL REPORTS (2022)
NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion
Ying Wu et al.
ACTA PHARMACEUTICA SINICA B (2022)
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Jun Wang et al.
NATURE CELL BIOLOGY (2022)
Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2
Brandon Dale et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
PROTAC mediated FKBP12 degradation enhances Hepcidin expression via BMP signaling without immunosuppression activity
Tianbai Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6
Zhuoxian Cao et al.
ACS CHEMICAL BIOLOGY (2021)
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
Shipeng He et al.
ACTA PHARMACEUTICA SINICA B (2021)
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
Zhihao Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs
Robert P. Law et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein
Zhiwen Qi et al.
BIOORGANIC CHEMISTRY (2021)
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
Bo Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
Yalin Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
Ming He et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Yuan Xiong et al.
CELL CHEMICAL BIOLOGY (2021)
There's more to death than life: Noncatalytic functions in kinase and pseudokinase signaling
Peter D. Mace et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
Hongying Gao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis
Lioubov Korotchkina et al.
LEUKEMIA (2020)
Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase
Ka Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
Hongying Gao et al.
PROTEIN & CELL (2020)
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Anja Vogelmann et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Bikash Adhikari et al.
NATURE CHEMICAL BIOLOGY (2020)
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Daniela Tomaselli et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer
M. Cynthia Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Jian Cao et al.
TRENDS IN CANCER (2020)
AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
Kai-li Zhang et al.
ACTA PHARMACOLOGICA SINICA (2019)
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Hao Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Advances in epigenetics link genetics to the environment and disease
Giacomo Cavalli et al.
NATURE (2019)
Development of selective small molecule MDM2 degraders based on nutlin
Bo Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
Yangbing Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming
Agnes L. C. Ong et al.
AGEING RESEARCH REVIEWS (2018)
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Ka Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Malik Bisserier et al.
BLOOD (2018)
A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response
Takayuki Hoshii et al.
CELL (2018)
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors
Renato Ferreira de Freitas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis
Shao-Jie Zhou et al.
ONCOLOGY LETTERS (2018)
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
Xun Huang et al.
CELL (2018)
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Philipp M. Cromm et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
SirT3 and p53 Deacetylation in Aging and Cancer
Jijun Chen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Selective Histone Deacetylase Inhibitors with Anticancer Activity
Nan Ma et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine
Ambra A. Grolla et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma (vol 24, pg 75, 2013)
Markus Brockmann et al.
CANCER CELL (2016)
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease
Sri N. Batchu et al.
CLINICAL SCIENCE (2016)
TP53 variations in human cancers: new lessons from the IARC TP53 Database and genomic studies
M. Olivier et al.
EUROPEAN JOURNAL OF CANCER (2016)
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities
Hang Chen et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes
Brittelle E. Kessler et al.
MOLECULAR CANCER RESEARCH (2016)
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
Daniel Dauch et al.
NATURE MEDICINE (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype
Feimeng Zheng et al.
NATURE COMMUNICATIONS (2016)
Targeting FAK scaffold functions inhibits human renal cell carcinoma growth
Claire Beraud et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia
Valentina Audrito et al.
BLOOD (2015)
EZH2: biology, disease, and structure-based drug discovery
Jin-zhi Tan et al.
ACTA PHARMACOLOGICA SINICA (2014)
Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer
Priyanka N. Gogate et al.
CANCER LETTERS (2014)
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Claudia C. S. Chini et al.
CLINICAL CANCER RESEARCH (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
HDAC6 Deacetylates and Ubiquitinates MSH2 to Maintain Proper Levels of MutSα
Mu Zhang et al.
MOLECULAR CELL (2014)
EZH2 expands breast stem cells through activation of NOTCH1 signaling
Maria E. Gonzalez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
By Fabrizio Montecucco et al.
CURRENT DRUG TARGETS (2013)
FK506-binding protein 12 ligands: a patent review
Fei Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells METABOLIC BASIS AND POTENTIAL CLINICAL IMPLICATIONS
Bo Tan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation
Hae-Yun Jung et al.
MOLECULAR CELL (2013)
Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions
Elena Maldi et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer
Kyung Hyun Yoo et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
A kinase-independent role for Aurora A in the assembly of mitotic spindle microtubules in Caenorhabditis elegans embryos
Mika Toya et al.
NATURE CELL BIOLOGY (2011)
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Jie Xu et al.
NATURE CHEMICAL BIOLOGY (2011)
FOCAL ADHESION KINASE: EXPLORING FAK STRUCTURE TO GAIN INSIGHT INTO FUNCTION
Jessica E. Hall et al.
INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 288 (2011)
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes
A. Garten et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
Michael D. Schaller
JOURNAL OF CELL SCIENCE (2010)
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
Pierre Beauparlant et al.
ANTI-CANCER DRUGS (2009)
The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
Mark Watson et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation
Ssang-Taek Lim et al.
MOLECULAR CELL (2008)
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions
Agustin Valenzuela-Fernandez et al.
TRENDS IN CELL BIOLOGY (2008)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
HDAC6 modulates cell motility by altering the acetylation level of cortactin
Xiaohong Zhang et al.
MOLECULAR CELL (2007)
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells
Bin Shi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Epigenetics: A landscape takes shape
Aaron D. Goldberg et al.
CELL (2007)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes
A Willis et al.
ONCOGENE (2004)
Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes
SS Hook et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Identification of components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination signaling pathways
D Seigneurin-Berny et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
